Get Cash Back and $0 Commissions + The Power of TradeStation
New Research Coverage Highlights Sanofi, Amdocs, GlaxoSmithKline plc, BT Group, Sociedad Quimica y Minera S.A, and ARMOUR Residential REIT Consolidated Revenues, Company Growth, and Expectations for 2018
Globe Newswire 26-Sep-2018 8:50 AM
NEW YORK, Sept. 26, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Sanofi (NYSE:SNY), Amdocs Limited (NASDAQ:DOX), GlaxoSmithKline plc (NYSE:GSK), BT Group PLC (NYSE:BT), Sociedad Quimica y Minera S.A. (NYSE:SQM), and ARMOUR Residential REIT, Inc. (NYSE:ARR), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Fundamental Markets, available for free download at the links above, examine Sanofi (NYSE:SNY), Amdocs Limited (NASDAQ:DOX), GlaxoSmithKline plc (NYSE:GSK), BT Group PLC (NYSE:BT), Sociedad Quimica y Minera S.A. (NYSE:SQM), and ARMOUR Residential REIT, Inc. (NYSE:ARR) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed September 24th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
SANOFI (SNY) REPORT OVERVIEW
Sanofi's Recent Financial Performance
For the twelve months ended December 31st, 2017 vs December 31st, 2016, Sanofi reported revenue of $40,921.38MM vs $38,407.87MM (up 6.54%) and analysts estimated basic earnings per share $3.79 vs $2.03 (up 87.27%). Analysts expect earnings to be released on October 31st, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $1.00. The estimated EPS forecast for the next fiscal year is $3.32 and is expected to report on February 6th, 2019.
For the three months ended June 30th, 2018 vs June 30th, 2017, Amdocs reported revenue of $1,002.20MM vs $966.70MM (up 3.67%) and analysts estimated basic earnings per share $0.64 vs $0.82 (down 21.95%). For the twelve months ended September 30th, 2017 vs September 30th, 2016, Amdocs reported revenue of $3,867.16MM vs $3,718.23MM (up 4.01%) and analysts estimated basic earnings per share $2.99 vs $2.74 (up 9.12%). Analysts expect earnings to be released on November 14th, 2018. The report will be for the fiscal period ending September 30th, 2018. Reported EPS for the same quarter last year was $0.88. The estimated EPS forecast for the next fiscal year is $4.05 and is expected to report on November 14th, 2018.
For the three months ended June 30th, 2018 vs June 30th, 2017, GlaxoSmithKline plc reported revenue of $9,948.91MM vs $9,360.82MM (up 6.28%) and analysts estimated basic earnings per share $0.25 vs $0.09 (up 158.99%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, GlaxoSmithKline plc reported revenue of $38,903.72MM vs $37,797.96MM (up 2.93%) and analysts estimated basic earnings per share $0.81 vs $0.51 (up 58.43%). Analysts expect earnings to be released on October 24th, 2018. The report will be for the fiscal period ending September 30th, 2018. Reported EPS for the same quarter last year was $0.85. The estimated EPS forecast for the next fiscal year is $2.99 and is expected to report on February 6th, 2019.
For the three months ended March 31st, 2018 vs March 31st, 2017, BT Group reported revenue of $8,297.15MM vs $7,661.16MM (up 8.30%) and basic earnings per share $0.16 vs $0.22 (down 27.53%). For the twelve months ended March 31st, 2018 vs March 31st, 2017, BT Group reported revenue of $31,473.30MM vs $31,456.25MM (up 0.05%) and analysts estimated basic earnings per share $1.03 vs $1.26 (down 18.33%). Analysts expect earnings to be released on July 27th, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was $0.40. The estimated EPS forecast for the next fiscal year is $1.66 and is expected to report on May 9th, 2019.
SOCIEDAD QUIMICA Y MINERA S.A. (SQM) REPORT OVERVIEW
Sociedad Quimica y Minera S.A's Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, Sociedad Quimica y Minera S.A reported revenue of $638.70MM vs $505.27MM (up 26.41%) and analysts estimated basic earnings per share $0.51 vs $0.38 (up 32.34%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Sociedad Quimica y Minera S.A reported revenue of $2,157.32MM vs $1,939.32MM (up 11.24%) and analysts estimated basic earnings per share $1.63 vs $1.06 (up 53.69%). Analysts expect earnings to be released on November 28th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $0.43. The estimated EPS forecast for the next fiscal year is $2.07 and is expected to report on February 27th, 2019.
For the three months ended June 30th, 2018 vs June 30th, 2017, ARMOUR Residential REIT reported revenue of $65.79MM vs $60.03MM (up 9.60%) and analysts estimated basic earnings per share $0.22 vs $0.70 (down 68.57%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, ARMOUR Residential REIT reported revenue of $254.43MM vs $264.00MM (down 3.62%) and analysts estimated basic earnings per share $4.22 vs -$1.67. Analysts expect earnings to be released on October 24th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $0.69. The estimated EPS forecast for the next fiscal year is $2.40 and is expected to report on February 13th, 2019.
Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.
REGISTERED MEMBER STATUS
Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
